Regression of Subependymal Giant Cell Astrocytoma With Rapamycin in Tuberous Sclerosis Complex

The authors present a 21-year-old woman who has been receiving rapamycin for 5 months for bilateral subependymal giant cell astrocytomas. The patient was started at a dose of 0.2 mg/kg/day. Levels were maintained between 11 and 13 ng/mL. Magnetic resonance imaging of the brain 2½ months after initia...

Full description

Saved in:
Bibliographic Details
Published in:Journal of child neurology 2008-10, Vol.23 (10), p.1238-1239
Main Authors: Koenig, Mary Kay, Butler, Ian J., Northrup, Hope
Format: Article
Language:English
Subjects:
Antibiotics, Antineoplastic - administration & dosage
Brain - drug effects
Brain - pathology
Brain Neoplasms - drug therapy
Brain Neoplasms - pathology
Brain Neoplasms - physiopathology
Dose-Response Relationship, Drug
Female
Glioma, Subependymal - drug therapy
Glioma, Subependymal - pathology
Glioma, Subependymal - physiopathology
Humans
Magnetic Resonance Imaging
Sirolimus - administration & dosage
Treatment Outcome
Tuberous Sclerosis - drug therapy
Tuberous Sclerosis - pathology
Tuberous Sclerosis - physiopathology
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The authors present a 21-year-old woman who has been receiving rapamycin for 5 months for bilateral subependymal giant cell astrocytomas. The patient was started at a dose of 0.2 mg/kg/day. Levels were maintained between 11 and 13 ng/mL. Magnetic resonance imaging of the brain 2½ months after initiating rapamycin demonstrated a decrease in size of both astrocytomas (11 to 7.5 mm on the right and 8 to 5 mm on the left). Further studies are needed with prolonged observation to confirm these findings, determine the length of necessary treatment, and evaluate recurrence risk after discontinuation of rapamycin.
ISSN:0883-0738
1708-8283
DOI:10.1177/0883073808321764